| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human RIM1/RIMS1 recombinant protein (Position: K49-E1456) was used as the immunogen for the RIMS1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
RIMS1 Antibody / Regulating synaptic membrane exocytosis protein 1 is a anti-RIMS1 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Immunohistochemistry (IHC), ELISA with listed reactivity in Mouse, Rat.
Key elements and design rationale
- Target: RIMS1
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, IHC, ELISA
Biological background
Structurally, RIMS1 contains zinc finger, PDZ, C2A, and C2B domains that mediate interactions with Munc13, RAB3A, ELKS, liprins, and calcium channels. Through these interactions, RIMS1 facilitates vesicle tethering, calcium channel clustering, and efficient neurotransmitter release. It localizes to the cytoplasmic face of active zones in excitatory and inhibitory neurons, where it serves as a molecular hub integrating presynaptic signaling and vesicle dynamics.
The RIMS1 antibody is used in neurobiology and synaptic physiology research to study synaptic vesicle trafficking, neurotransmitter release, and presynaptic organization. Western blot analysis typically identifies a 175-180 kilodalton band corresponding to RIMS1, while immunofluorescence reveals punctate staining at presynaptic terminals. This antibody supports studies of neuronal communication, synaptic plasticity, and calcium-dependent exocytosis.
Mutations in RIMS1 are associated with cone-rod dystrophy and autism spectrum disorders, highlighting its importance in both neuronal development and sensory transmission. RIMS1 deficiency disrupts synaptic organization and impairs neurotransmitter release efficiency. The RIMS1 antibody is a key reagent for analyzing synaptic machinery and presynaptic protein complexes.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
